TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07147231: Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite St

Sponsor: National Cancer Institute (NCI) · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 86 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$3,298,680

Rescue Site Savings

+$2,159,850

Unlock Full NCT07147231 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07147231 Rescue Dossier →